Market Overview

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc.

Share:

Biologics,
Inc.
, a McKesson
Specialty Health
oncology, neurology and complex care pharmacy
services company, has been selected by Agios Pharmaceuticals, Inc. to be
in the limited distribution network for TIBSOVO®
(ivosidenib), an IDH1 inhibitor approved by the U.S. Food and Drug
Administration (FDA) for the treatment of adult patients with
relapsed/refractory acute myeloid leukemia (AML) with a susceptible
isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA
approved test. The addition of this critical medicine brings the total
number of oncology and supportive therapies accessible through Biologics
to 118. Approval was granted by the FDA on July 20, 2018.

"Previously, patients with relapsed/refractory IDH1 mutant AML have had
limited treatment options," said Brandon Tom, vice president, Commercial
Services, McKesson Specialty Health. "We are pleased to be able to offer
this much-needed new drug to these patients, which accounts for
approximately 6-10 percent of all AML patients."

Biologics' specialty pharmacy is committed to and recognized for its
high level of customer service as well as its innovative, high-touch and
multidisciplinary patient-centric approach. Each team includes a
pharmacist with in-depth knowledge of oncology therapies, an experienced
oncology nurse and a financial counselor who is familiar with various
financial assistance programs and organizations that help cancer
patients. This highly-skilled care team works together to develop
individualized care plans that address each patient's unique clinical,
financial and emotional needs and streamlines communication back to the
treating provider, enabling high-quality care and differentiated
outcomes. In addition, the Biologics team works closely with payers to
ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone
(800-850-4306), fax (800-823-4506) or eScribe. For electronic
prescribing systems, physicians may search for Biologics within their
EMR system.

About Biologics

Biologics, Inc. is an oncology and complex care pharmacy services
company that enables healthcare providers, payers and biopharma to
optimize cancer care for the best possible outcomes – clinical,
financial and emotional. Unifying fragmented healthcare services,
Biologics brings efficiency and humanity to oncology care management by
focusing on the patient's best interest as the surest path to managing
cost and risk.

Biologics is part of McKesson Specialty Health, a division
of McKesson Corporation empowering the community patient care delivery
system by helping community practices advance the science, technology
and quality of care. Through innovative clinical research, business and
operational solutions, facilitated by integrated technology systems, we
focus on improving the financial health of our customers so they may
provide the best care to their patients. Our combined organization will
help better support patients and expedite access to oncology therapies.
For more information, visit www.mckessonspecialtyhealth.com
and www.biologicsinc.com.

View Comments and Join the Discussion!